Welcome to our dedicated page for aTYR PHARMA SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTyr Pharma, Inc. (ATYR) is asking stockholders at a special meeting on October 16, 2026 to approve amendments to its certificate of incorporation that would authorize the Board to implement a reverse stock split of the common stock at a ratio between 1‑for‑10 and 1‑for‑50, at the Board’s discretion within one year of approval. The Board states the main goal is to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a deficiency notice and an extension to November 30, 2026, and to increase marketability and flexibility by effectively expanding available authorized but unissued shares. The Board may choose any ratio in the approved range, or decide not to implement a reverse split at all. Each holder’s ownership percentage would remain essentially unchanged, with fractional shares rounded up to the nearest whole share.
aTyr Pharma, Inc. (ATYR) is asking stockholders at an October 16, 2026 special meeting to approve amendments to its certificate of incorporation that would authorize the Board, in its sole discretion, to implement a reverse stock split of the common stock at any ratio between 1‑for‑10 and 1‑for‑50 within one year of approval.
The main stated goal is to help regain and maintain compliance with Nasdaq’s $1.00 minimum bid price requirement after the company received deficiency notices and an extended compliance deadline to November 30, 2026, and to potentially improve marketability and liquidity of the shares. A reverse split would not change each holder’s percentage ownership, aside from rounding up fractional shares, but would reduce shares outstanding while leaving the 340,000,000 authorized common shares unchanged, effectively increasing the pool of authorized but unissued shares, which could later be used for financing or other corporate purposes.
The proxy describes risks such as the possibility that the post‑split price may not stay above $1.00, potential reduced liquidity and more odd-lot holdings, and that the enlarged pool of authorized but unissued shares could have anti‑takeover implications. As of August 27, 2026, there were 98,087,425 shares outstanding; Federated Hermes, Inc. beneficially owned 8.68%, while all directors and executive officers as a group held 5.03%.
aTyr Pharma is a clinical-stage biotech focused on tRNA synthetase biology for fibrosis and inflammation. For the quarter ended June 30, 2026, it reported a consolidated net loss of $10.3 million (basic and diluted net loss per share of $0.11) and total operating expenses of $10.9 million, with research and development at $6.7 million and general and administrative at $4.1 million.
Cash, cash equivalents, restricted cash and available-for-sale investments totaled $58.9 million, and the company believes this will fund material cash requirements for at least one year. Net cash used in operating activities was $21.9 million for the first half of 2026. aTyr maintains an at-the-market equity program but did not use it in the period.
Lead candidate efzofitimod missed the primary endpoint in the prior EFZO-FIT Phase 3 pulmonary sarcoidosis trial but showed nominal improvements in several clinical measures. After FDA feedback, aTyr plans a new global Phase 3 study using forced vital capacity as the primary endpoint. The company is also running a Phase 2 SSc-ILD study (EFZO-CONNECT) and advancing ATYR0101 into IND-enabling work. A restructuring approved in August 2026 will reduce headcount by about 60% to 20 employees, with estimated $4.2 million in severance-related charges and expected annualized operating expense reductions of about $13 million. Rights to develop and commercialize efzofitimod in Japan reverted to aTyr following termination of its Kyorin collaboration, and the company disclosed ongoing putative securities class actions related to efzofitimod.
aTyr Pharma reported second quarter 2026 results and a major restructuring to prioritize its efzofitimod program for interstitial lung disease. Operating expenses were $10.9 million, including research and development of $6.7 million and general and administrative of $4.1 million, leading to a net loss attributable to aTyr of $10.3 million, or $0.11 per share, compared with $19.5 million, or $0.22 per share, a year earlier. Cash, cash equivalents, restricted cash and investments were $58.9 million as of June 30, 2026.
The company plans a workforce reduction of approximately 60% and other cost-saving measures it expects will reduce annualized operating expenses by about $13 million beginning in the fourth quarter of 2026 and support a cash runway into late 2028 while focusing resources on efzofitimod. Chief Financial Officer Jill Broadfoot and General Counsel Nancy Denyes will step down on September 30, 2026 and transition to consulting roles; Vice President of Finance Brandon Yaras will become CFO on October 1, 2026.
aTyr is awaiting U.S. Food and Drug Administration feedback by the end of August 2026 on a protocol for a planned global Phase 3 study of efzofitimod in pulmonary sarcoidosis and has completed enrollment in the Phase 2 EFZO-CONNECT study in SSc-ILD, with topline data expected in the first quarter of 2027.
FMR LLC and Abigail P. Johnson report passive ownership of ATYR PHARMA INC common stock on an amended Schedule 13G. FMR LLC beneficially owns 2,471,418 shares, representing 2.5% of the common stock outstanding. FMR LLC has sole voting power over 2,464,141 of these shares and sole dispositive power over the full 2,471,418 shares, with no shared voting or dispositive power reported.
Abigail P. Johnson is reported as having sole dispositive power over the same 2,471,418 shares, but no sole or shared voting power, reflecting her control position over FMR-related entities. The filing confirms ownership of 5 percent or less of the class and notes that one or more other persons may receive dividends or sale proceeds, although no other person’s interest exceeds five percent of ATYR PHARMA INC’s common stock.
aTyr Pharma, Inc. entered into a Termination Agreement with Kyorin Pharmaceutical Co., Ltd. effective July 30, 2026, formally ending their 2020 collaboration and license arrangement for efzofitimod in Japan. All licenses Kyorin held under the prior agreement, including exclusive rights to develop and commercialize efzofitimod for interstitial lung disease in Japan, ceased on the termination date, and those exclusive territorial rights reverted to aTyr. As a result, aTyr now holds the right to develop and commercialize efzofitimod globally.
Under the agreement, Kyorin grants aTyr worldwide, irrevocable, perpetual, royalty‑free licenses to Kyorin Background Technology (non‑exclusive) and to New Kyorin IP and Kyorin’s interest in New Joint IP (exclusive) related to the Reversion Products. Kyorin will transfer extensive clinical, regulatory and manufacturing data, including Handover Documents and Essential Documents, and will assign to aTyr the Japanese orphan drug designation for efzofitimod, while continuing certain sponsor responsibilities and archival obligations during a transition period of up to twelve (12) months. The parties mutually release claims under the prior collaboration arising before the termination date and confirm there are no outstanding development cost payments owed by Kyorin to aTyr.
BlackRock, Inc. filed an amended Schedule 13G reporting its passive ownership in aTYR PHARMA INC common stock. BlackRock reports beneficial ownership of 1,725,072 shares of common stock, representing 1.8% of the class.
BlackRock has sole voting power and sole dispositive power over all 1,725,072 shares, with no shared voting or dispositive power. Various underlying clients or funds have rights to dividends or sale proceeds, but no single person’s interest exceeds five percent of aTYR PHARMA’s outstanding common shares.
Federated Hermes, Inc. filed an amendment on Schedule 13G/A reporting beneficial ownership of 8,509,678 shares of common stock of aTYR PHARMA INC, equal to 8.68% of the class as shown on the cover pages dated 06/30/2026. The filing includes a Rule 13d-4 disclaimer that Federated Hermes, the Voting Shares Irrevocable Trust and related individuals expressly disclaim beneficial ownership of securities held by the managed funds.
aTyr Pharma, Inc. received an additional 180-day period from Nasdaq to regain compliance with the exchange’s minimum bid price requirement for continued listing. The company now has until November 30, 2026 for its stock to close at or above $1.00 for at least 10 consecutive business days.
The extension was granted because aTyr meets other Nasdaq Capital Market listing standards, including market value of publicly held shares, and has stated its intention to cure the deficiency, potentially through a reverse stock split. The company’s shares remain listed while it monitors its stock price and evaluates options.
ATYR PHARMA INC reports an Amendment No. 14 to a Schedule 13G/A disclosing that FMR LLC beneficially owns 5,935,900 shares of Common Stock, representing 6.1% of the class. The filing lists voting and dispositive powers attributed to FMR LLC and Abigail P. Johnson and references an exhibit concerning a 13d-1(k) agreement.